GE Healthcare Obtains License for c-Met Peptides from Dyax | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dyax is granting GE Healthcare rights to develop and commercialize c-Met imaging peptides for potential use in patient selection under a deal announced today.

Under the terms of the deal, GE will pay biopharmaceutical firm Dyax upfront, milestone, and royalty payments. Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.